Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Core Insights - Teva Pharmaceuticals has received FDA approval for a generic version of Saxenda (liraglutide injection), marking the first-ever generic GLP-1 product specifically indicated for weight loss in the U.S. market [1][2][7] - The launch of this generic is part of Teva's strategy to expand its complex generics portfolio and is the fifth first-to-market entry for the company in 2025 [2][7] - Saxenda generated annual sales of $165 million as of June 2025, indicating a significant market opportunity for Teva's generic version [2] Company Strategy - The approval and launch of the generic Saxenda align with Teva's "Pivot to Growth" strategy, emphasizing the company's commitment to complex generic medicines [7] - Teva aims to address the increasing demand for weight loss therapies in the U.S. market through this new product [7] Product Information - Liraglutide injection is indicated for adults with obesity or overweight who have weight-related medical problems, as well as for pediatric patients aged 12-17 years with obesity [3][7][8] - The product should be used in conjunction with a reduced-calorie diet and increased physical activity to achieve weight loss and maintain weight reduction [3][7] Market Context - The introduction of the generic Saxenda is expected to enhance competition in the GLP-1 therapy market, which has seen rising demand for weight loss solutions [7] - Teva's entry into this segment may influence pricing and accessibility for patients seeking weight management options [7]